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Cordyceps militaris (CM) is an insect-borne fungus that has been used in traditional Chinese medicine because of its wide range
of pharmacological activities. In this paper, we studied CM grown on germinated soybean (GSC) and investigated the possible
mechanisms underlying antiproliferative eﬀect of GSC on HT-29 human colon cancer cells. In comparison with CM extracts
and germinated soybean (GS) BuOH extracts, BuOH extracts of GSC showed remarkable inhibitory and antiproliferative eﬀects
on HT-29 colon cancer cells. After GSC treatment, HT-29 cells became smaller and irregular in shape. High G2/M phase cell
populations were observed in the GSC-treated group. The levels of cyclin B1 and Cdc25 in the GSC-treated group were lower than
those in the control group. These ﬁndings suggest that GSC BuOH extracts might act as an eﬀective anti-proliferative agent by
inducing G2/M cell cycle arrest in colon cancer cells.
1.Introduction
Colon cancer is a serious public health problem in the
Western world [1]. According to the American Cancer
Society, colon cancer is the second leading cause of cancer-
related deaths in the United States (US). Patient survival is
related to the tumor stage. For example, stage I colorectal
cancer, in which the carcinoma remains localized in the
submucosa of the colon epithelium, has an overall 5-year
survival rate of over 90% while the 5-year survival rate
for stage IV cancer is less than 10%. The dysregulation of
cell cycle found in some cancers. A large number of cells
show modulated expression of the molecules responsible for
apoptosis and cell cycle arrest [2], including cyclins and
cyclin-dependent protein kinases (CDKs).
Current therapies for cancer are largely based on cancer-
speciﬁc surgery, hormone therapy, radiotherapy, chemother-
apy, and treatment with anticancer drugs. While advances
continue to be made in the development of eﬀective strat-
egies for treating colorectal cancer, chemotherapy is often
limited by the severe adverse eﬀects and dose-limiting
toxicity of the drugs. Therefore, it is extremely essential to
identify and screen compounds from natural products that
can eﬀectively treat cancer with no adverse eﬀects.
A large number of medicinal mushrooms have been
proven to possess anticancer activities [3–6]. One such
mushroom, Cordyceps militaris (CM) has been used in tra-
ditional Chinese medicine. CM extracts have been reported
to exert a wide range of pharmacological activities, includ-
ing immunomodulatory, anti-inﬂammatory, and antitumor
activities [7–10]. Kim et al. [11]a n dP a r ke ta l .[ 7]r e p o r t e d
that CM has potent cytotoxic eﬀect against cancer cells
and exerts immunostimulatory eﬀects. Jin et al. reported
that aqueous CM extracts induced apoptosis in human
breast cancer MDA-MB231 cells by activating caspases and
inactivating Akt [12].
Despite the clinical and pharmacological importance
of CM, naturally occurring CM is not easily available in
large quantities because of its high cost of production.
Therefore, we developed novel methods for cultivating CM.
We successfully cultivated CM on germinated soybeans
(GS), which contain a large number of nutrients and active2 Evidence-Based Complementary and Alternative Medicine
biological compounds such as isoﬂavones [13, 14]. In our
previous study, we demonstrated that CM cultivated on GS
(GSC) shows better pharmacological activity than naturally
occurring CM [10, 15]. However, the activity of GSC against
colon cancer carcinogenesis has not been clearly stated. In
this study, we investigated the eﬀect of GSC on HT-29
colon cancer cells and determined the molecular mechanism
underlying this eﬀect.
2.MaterialsandMethods
2.1. Reagents and Chemicals. GSC, CM, and GS (Kucari
0903) were obtained from The Cell Activation Research
Institute,Seoul,RepublicofKorea.RPMI1640medium,fetal
bovine serum (FBS), penicillin-streptomycin, and trypsin-
EDTA were obtained from Gibco BRL (Grand Island, NY,
USA). Propidium iodide (PI), NP-40, and RNase A were
obtained from Sigma Chemical Co. (St. Louis, MO, USA).
Anti-Cdc25c (Cell Signaling Technology Inc., Danvers, MA),
anticyclin B1 (Cell Signaling Technology Inc., Danvers, MA),
anti-Bcl2 (Cell Signaling Technology Inc., Danvers, MA),
anticaspase-9(CellSignalingTechnologyInc.,Danvers,MA),
anti-β-actin, horseradish peroxidase- (HRP-) conjugated
anti-rabbit, and anti-mouse IgG antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) were obtained from the
respective suppliers. The chemiluminescence detection kits
were purchased from Biosesang (Seoul, Republic of Korea)
and EZ-CyTox assay kit from Daelillab service Co. (Republic
of Korea).
2.2. Preparation of GSC. GSC was grown as previously de-
scribed [10]. An authenticated voucher specimen of CM
(Kucari 0903) as deposited in the Herbarium at the College
of Bioscience and Biotechnology, Konkuk University (Seoul,
Republic of Korea). Brieﬂy, the CM mycelium (Kucari 0906)
was inoculated on germinated soybeans (Glycine max (L.)
Merr), and cultured at 20–25◦C for 4 weeks. The powdered
material (1kg) was extracted under reﬂux with 80% MeOH
(methanol extract of GSC (GSCM)) for 48h. The total
extract (178g, yield (w/w), 17.8%) was dissolved with water.
After removing the insoluble solid particles by ﬁltration,
the liquid phase was extracted sequentially by solvents with
increasing polarity (hexane, EtOAc, BuOH, and water; 1:10
(w/v) for all solvents) to yield 4 fractions. The liquid-liquid
phase extraction was performed in Erlenmeyer ﬂasks by
shaking, and the extracts were concentrated to dryness by a
rotary evaporator. Thus, weobtained the following fractions:
hexane fraction (16g, yield (w/w) 1.6%), EtOAc fraction
(4.5g, yield (w/w) 0.45%), BuOH fraction (8.25g, yield
(w/w) 0.825%), and water fraction (10.86g, yield (w/w)
1.086%).
2.3. Cell Culture. The HT-29 cells (human colon cancer
cells) were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). Cells were cultured
in RPMI 1640 medium (Gibco, Grand Island, NY, USA)
supplemented with 10% heat-inactivated FBS (Gibco, Grand
Island, NY, USA), 100U/mL of penicillin, and 100μg/mL
streptomycin at 37◦C in a humidiﬁed incubator with 5%
CO2.
2.4. Cell Proliferation Assay. The eﬀect of GSC, GS, and CM
BuOH extract on HT-29 cell proliferation was measured
using the EZ-CyTox kit (Daelillab service Co., Republic of
Korea). The assay was performed as per the manufacturer’s
protocol. HT-29 colon cancer cells (1 × 104 cells/well)
were placed in a 96-well plate and incubated with various
concentrations (0, 25, 50, 75, 100, and 250μg/mL) of GSC
BuOH, GS BuOH, and CM BuOH extracts for 48h and 72h,
respectively. A ﬁxed amount (10μL) of EZ-CyTox reagent
was added to each well and incubated for an additional 1-2h
at 37◦C. Cell proliferation levels were detected at an optical
density (OD) of 450nm by using an ELISA Multidetection
Reader (Tecan, Mannedorf, Switzerland).
2.5. Morphological Analysis. HT-29 cells were placed in 6-
well plates at a density of 1 × 106 cells/mL. After 24h incu-
bation, the cells were treated with diﬀerent concentrations
of GSC BuOH extract. After 48h, the cells were ﬁxed with
3% formaldehyde and then observed under a phase-light
microscope (Olympus, Tokyo, Japan) and photographed at a
magniﬁcation of 100x to detect any morphological changes.
2.6. Cell Cycle Analysis. HT-29 cells (1 × 106 cells/mL) were
incubated in 6-well plates in the presence or absence of
GSC BuOH extract for 48h, after which they were harvested
by trypsinization, washed twice with phosphate buﬀered
saline (PBS), and ﬁxed with 70% ice-cold ethanol. After
centrifugation, the ﬁxed cells were incubated with a staining
solution containing 0.2% NP-40, RNase A (30μg/mL), and
PI (50μg/mL) (Sigma, St. Louis, USA) in a phosphate-citrate
buﬀer (pH 7.2). Cellular DNA content was analyzed by
ﬂow cytometry using a Becton Dickinson laser-based ﬂow
cytometer (Becton Dickinson, New Jersey, USA). At least
10,000 cells were used for each analysis, and the results
were displayed as histograms. The average percentage of
cells in each phase of the cell cycle was determined over 3
independent experiments.
2.7. Western Blotting Analysis. The HT-29 cells were treated
w i t hG S CB u O He x t r a c t sa tc o n c e n t r a t i o n so f0 ,2 5 ,5 0 ,
75, 100, and 250μg/mL for 48h. Cells were lysed in the
lysis buﬀer and the protein concentration was determined
using a protein assay kit (Thermoscientiﬁc, Rockford, USA)
with bovine serum albumin as the standard. Samples with
equal amounts of protein were analyzed by 12% SDS-PAGE.
The proteins were transferred to a polyvinylidene ﬂuoride
(PVDF) membrane using a transfer buﬀer. The membranes
were incubated overnight at 4◦C with a blocking buﬀer (1×
PBS-T and 5% skim milk) and then incubated with anti-
bodies against Cdc25c, cyclin B1, Bcl2, caspase-9 (1:2,000),
and β-actin (1:3,000) for 2-3h at room temperature with
constant shaking. The membranes were washed three times
in a 1× PBS-T buﬀer and incubated with HRP-conjugated
secondary antibodies (1:5,000) for 1-2h. The membranes
werewashedanddetectionoftheimmunoreactivebandswasEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Anti-proliferative eﬀects of GSC, GS, and CM BuOH extract on HT-29 cells. (a) HT-29 cells (1 × 104/well) were treated
with various concentrations (0, 25, 50, 75, 100, and 250μg/mL) of GSC, GS, CM BuOH, extract and 25μg/mL of doxorubicin for 48h.
Doxorubicin, a potent anticancer agent, was used as the positive control. The HT-29 cell proliferation was determined by the EZ-CyTox
assay. One-way ANOVA followed by Dunnett’s t-test was used for comparisons of multiple group means (aP<0.001 or bP<0.0005 versus
blank). (b) Eﬀect of GSC BuOH extract on HT-29 cell proliferation. Time-dependent inhibition of HT-29 cell proliferation by the GSC
BuOH extracts. The growth inhibition was calculated as a percentage of inhibition and compared with the values for the control. One-way
ANOVA followed by Dunnett’s t-test was used for comparisons of multiple group means (∗P<0.001 versus control (48h), #P<0.001 or
##P<0.0005 versus control (72h), ∗P<0.01 control (48h) versus control (72h)). GSC, Cordyceps militaris g r o w no ng e r m i n a t e ds o y b e a n ;
GS, germinated soybean; CM, Cordyceps militaris.
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Figure 2: Eﬀect of GSC BuOH extract on morphological changes in HT-29 colon cancer cells. HT-29 cells were treated with the following
concentrations of GSC BuOH for 48h. (a) 0μg/mL, (b) 25μg/mL, (c) 50μg/mL, (d) 75μg/mL, (e) 100μg/mL, and (f) 250μg/mL of GSC
BuOH extract. The cell morphology was photographed by EVOS inverted microscope at 100x (Advanced Microscopy Group, Mill Creek,
USA). The arrow indicates cells with irregular size and shape. The arrowhead indicates single cells and loss of colony formation (bar =
100μm). GSC, Cordyceps militaris grown on germinated soybean.4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: GSC BuOH extract induced G2/M phase cell cycle arrest in HT-29 cells. Cell cycle progression was examined by ﬂow cytometry.
(a) 0μg/mL, (b) 25μg/mL, (c) 50μg/mL, (d) 75μg/mL, (e) 100μg/mL, and (f) 250μg/mL. One representative of 3 independent experiments
is shown (48h treatments). Histograms show the ﬁndings during sub-G1, G1/G0, S, and G2/M phases of HT-29 cells. One-way ANOVA
followed by Dunnett’s t-test was used for comparisons of multiple group means (∗P<0.05 or ∗P<0.001 versus control).
performed using the enhanced chemiluminescence western
blotting detection system (Biosesang, Seoul, Republic of
Korea).
2.8. Statistical Analysis. Values are presented as percentage ±
SDofcontrol.Student’st-testorone-wayANOVA/Dunnett’s
t-test was used to analyze the statistical signiﬁcance between
the CM-treated and control groups. Statistical analysis was
performed using SPSS, version 12 (SPSS Inc., Chicago, IL,
USA).
3. Results
3.1. GSC Treatment Inhibited HT-29 Colon Cancer Cell
Proliferation and Induced Changes in HT-29 Cell Morphology.
In comparison with the GS and CM BuOH extracts, GSC
BuOH extract showed a signiﬁcant inhibitory eﬀect on the
growth of HT-29 cells (Figure 1(a)). After a 48h treatment
with 100μg/mL of GSC BuOH, GS BuOH, and CM BuOH
extracts,theproliferationofHT-29cellsreducedby46.56%±
3.55%, 42.56% ± 2.99%, and 36.23% ± 0.46%, respectively.
Therefore, further experiments were conducted using the
GSC BuOH extract. As shown in Figure 1(b),G S CB u O H
extracts signiﬁcantly inhibited HT-29 cell proliferation in
a concentration- and time-dependent manner. However,
GSC BuOH extracts did not aﬀect cell viability of mouse
macrophage RAW264.7 (data not shown).
We also found morphological changes in HT-29 cells
after GSC BuOH extract treatment (Figure 2). After treat-
ment with GSC BuOH (0, 25, 50, 75, 100, and 250μg/mL)
for 48h, the cells showed morphological features such as loss
of colony formation and irregular size and shape, which were
not found in the cells of the control group.
3.2.GSCInducedG2/MPhaseCellCycleArrestinHT-29Cells.
Uncontrolled cell proliferation is a characteristic of cancer
cells [16]. To prove the inhibitory mechanism of GSC BuOH
extract against colon cancer cells, we examined the cell cycle
alterationofHT-29cellsbyﬂowcytometry.AfterGSCBuOH
extract treatment for 48h, the DNA contents of the G2/M
phase of HT-29 cells increased in a concentration-dependent
manner than those of the control group. The percentage of
cells in G2/M phase were 12.28% ±1.50%, 21.69% ±5.37%,
21.08% ± 4.80%, 26.69% ± 0.92%, and 30.21% ± 0.65%
compared to that in control (10.34%±1.06%), when treated
with25,50,75,100,and250μg/mLofGSCBuOHextractforEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Eﬀect of GSC BuOH extract on the protein expression levels of cyclin B1 and Cdc25c in HT-29 cells. (a) HT-29 cells were treated
with the indicated concentrations (0, 25, 50, 75, 100, and 250μg/mL) of GSC BuOH extract for 48h. Cell lysates were processed for western
blot analysis with anti-cyclin B1, anti-Cdc25c, anti-Bcl2, anticaspase-9, and anti-β-actin antibodies. Densitometric ((A)–(D)) analysis of 3
independent western blots (mean ± SD) expressed in terms of a percentage of the values for the control groups (∗P<0.05; ∗∗P<0.01;
∗∗∗P<0.005). (b) HT-29 cells were treated with 100μg/mL of GSC BuOH extract for 2, 6, 12, 24, and 48h. Cell lysates were processed
for western blot analysis with anti-cyclin B1, anti-Cdc25c, and anti-β-actin antibodies. β-Actin was used as an internal control. Figures are
representative of 3 independent experiments. Densitometric analysis of the bands of three western blots (mean ± SD) expressed in terms of
a percentage of the values for the control groups (∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.005).6 Evidence-Based Complementary and Alternative Medicine
48h, respectively (Figure 3). These results indicate that GSC
BuOH extract caused G2/M cell cycle arrest in HT-29 cells.
3.3. GSC Reduced the Protein Levels of Cyclin B1 and Cdc25c
in HT-29 Cells. To determine the molecular mechanisms
underlying the G2/M arrest by GSC BuOH extract, the levels
of the molecules involved in the G2/M phase of the cell
c y c l ew e r ec h e c k e d .G S CB u O He x t r a c t - t r e a t e dc e l l ss t r o n g l y
blocked the expression of cyclin B1 and Cdc25c protein in
HT-29 cells in a concentration-dependent (0, 25, 50, 75, 100,
and 250μg/mL) and time-dependent (0, 2, 6, 12, 24, and
48h) manner (Figures 4(a) and 4(b)). However, the GSC
BuOH extract had no eﬀect on the levels of apoptosis-related
proteins like Bcl2 and caspase-9 (Figure 4(a)).
4. Discussion
Due to the increasing incidences and relatively low remission
rates of colon cancers, there is a need to establish more eﬀec-
tive treatment regimens by adopting novel and innovative
approaches [16]. The use of active medicinal compounds
or extracts from traditional medicines or natural sources is
consideredasonesuchalternativetreatmentapproach.Many
naturally derived compounds/extracts are considered safe
as they are obtained from commonly consumed foodstuﬀs.
CM is a well-known medicinal mushroom that has been
used in oriental medicine for treating various diseases, in-
cluding cancers. Previous studies have demonstrated that
CM has a wide range of pharmacological activities, including
immunomodulatory and anti-inﬂammatory activities [7–
11].
Cancer cells generally exhibit few characteristics such as
high proliferation, migration, and matrix-invasion poten-
tials [17, 18]. Inhibition of tumor growth is one of the
therapeutic targets in the development of anticancer agents.
The regulation of tumor cell growth and the induction
of cell death are the 2 major ways to inhibit tumor
growth [19]. The present study evaluated whether GSC
BuOH extracts had anti-proliferative activities against HT-
29 cells. Although GSC BuOH, GS, and CM BuOH extracts
exhibited anti-proliferative activity against HT-29 cells, GSC
BuOH extracts showed anti-proliferative activity with the
lowest IC50 (100μg/mL) value. Severely distorted HT-29
cells and loss of colony formation ability were observed
after GSC BuOH treatment. We analyzed the changes in
HT-29 cell cycle progression after GSC BuOH treatment
by ﬂow cytometry. Cellular proliferation is controlled by
various genetically deﬁned checkpoints, which ensure the
progressionofcellsthroughthevariousstagesofthecellcycle
[20]. In cancer cells, cell cycle checkpoint control systems
are known to be disrupted through the accumulation of
mutations [21]. In the G2/M phase, damaged cells have the
opportunitytorepairDNAorpermanentlyarrestcellgrowth
if the degree of damage is severe [22]. Several anticancer
agents arrest the cell cycle in G2/M phase, and then induce
apoptosis and necrosis, resulting in cell death [23, 24]. In
general, the G2/M transition is regulated by a complex of
cell-division cyclins, namely, Cdc2 and a B-type cyclin [22].
The protein tyrosine phosphatase, Cdc25c, plays the role of
a mitotic activator by dephosphorylating Cdc2/p34, which
formstheCdc2/cyclinB1complexesthatpermitcellstoenter
into mitosis [25]. Many studies showed that Cdc2/p34 kinase
activity was enhanced in some human cancer cells because
of their genetic and epigenetic alterations [22]. Therefore,
we investigated whether the expressions of the molecules
involved in G2/M transition in HT-29 cells were altered
after GSC BuOH extract treatment. We found that GSC
t r e a t m e n tr e s u l t e di nd o w n r e g u l a t i o no fC d c 2 5 ca n dc y c l i n
B1 expression in HT-29 colon cancer cells. The results of
the present study indicated that GSC caused G2/M-phase
cell cycle arrest along with a decrease in the levels of cyclin
B1 and Cdc25c, which are involved in cell cycle progression
from the G2/M phase. In addition, the identiﬁcation of such
compounds will improve our understanding of the anti-
proliferative activities of GSC. Further experiments need to
be done to clarify the anti-proliferative mechanisms of these
identiﬁed compounds.
5. Conclusion
In conclusion, GSC BuOH extracts might act as an eﬀective
anti-proliferative agent by inducing G2/M cell cycle arrest in
colon cancer cells.
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